Nanthealth LLC (NYSE:NH)’s share price reached a new 52-week low on Monday . The stock traded as low as $10.58 and last traded at $10.75, with a volume of 50,396 shares trading hands. The stock had previously closed at $11.27.

Several equities research analysts have commented on NH shares. Cowen and Company started coverage on Nanthealth in a research note on Monday, June 27th. They issued an “outperform” rating and a $19.00 target price on the stock. Jefferies Group started coverage on Nanthealth in a research note on Monday, June 27th. They issued a “buy” rating on the stock. Canaccord Genuity started coverage on Nanthealth in a research note on Monday, June 27th. They issued a “buy” rating and a $17.00 target price on the stock. FBR & Co started coverage on Nanthealth in a research note on Monday, June 27th. They issued an “outperform” rating and a $18.00 target price on the stock. Finally, First Analysis started coverage on Nanthealth in a research note on Monday, June 27th. They issued an “overweight” rating and a $18.00 target price on the stock. Five equities research analysts have rated the stock with a buy rating, Nanthealth has a consensus rating of “Buy” and a consensus target price of $18.00.

The stock has a 50 day moving average price of $13.19 and a 200 day moving average price of $13.19. The company’s market cap is $5.95 billion.

In other Nanthealth news, CEO Patrick Soon-Shiong bought 357,143 shares of the firm’s stock in a transaction that occurred on Tuesday, June 7th. The stock was acquired at an average price of $14.00 per share, with a total value of $5,000,002.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Healthcare Solution Allscripts bought 714,286 shares of the firm’s stock in a transaction that occurred on Tuesday, June 7th. The shares were acquired at an average cost of $14.00 per share, with a total value of $10,000,004.00. Following the purchase, the insider now directly owns 15,000,000 shares of the company’s stock, valued at $210,000,000. The disclosure for this purchase can be found here.

Nant Health, LLC is an evidence-based, personalized healthcare company. The Company’s systems-based approach to personalized healthcare applies diagnostics tailored to the specific molecular profiles of patient tissues and integrates this molecular data in a clinical setting with real-time biometric signal and phenotypic data to track patient outcomes and deliver medicine.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.